Davis Polk advised Venus Medtech (Hangzhou) Inc. in connection with its placing of 18,500,000 new H shares for an aggregate consideration of approximately HK$1.2 billion (approximately US$153 million). 

Davis Polk also advised Venus Medtech in connection with its HK$2.59 billion (approximately US$331 million) IPO in December 2019.

Venus Medtech is the leading transcatheter heart valve medical device company in China, focusing on R&D, manufacturing and commercialization of products designed for transcatheter implantation to replace dysfunctional heart valves mainly associated with aortic stenosis and pulmonic, mitral and tricuspid regurgitation. Its self-developed product, VenusA-Valve, is the first TAVR product approved by the NMPA and commercialized in China.

The Davis Polk team included partner Yang Chu and associate Edwin Lee. All members of the Davis Polk team are based in the Hong Kong office.

 

Copy link to share post